Clinical characteristics and the role of IL-6 in acute-on-chronic liver failure patients with or without COVID-19: a multicenter paired cohort study
Background and AimsThe impact of coronavirus disease 2019 (COVID-19) on patients with acute-on-chronic liver failure (ACLF) remains unclear. To investigate the clinical characteristics of patients with ACLF complicated with COVID-19 in order to provide evidence for the precise treatment of this pati...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-01-01
|
| Series: | Frontiers in Cellular and Infection Microbiology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fcimb.2024.1471974/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850037307337342976 |
|---|---|
| author | Ruoyu Yao Guofen Xu Xiujuan Fu Wenrui Zhang Han Wang Yu Chen Jia Yao |
| author_facet | Ruoyu Yao Guofen Xu Xiujuan Fu Wenrui Zhang Han Wang Yu Chen Jia Yao |
| author_sort | Ruoyu Yao |
| collection | DOAJ |
| description | Background and AimsThe impact of coronavirus disease 2019 (COVID-19) on patients with acute-on-chronic liver failure (ACLF) remains unclear. To investigate the clinical characteristics of patients with ACLF complicated with COVID-19 in order to provide evidence for the precise treatment of this patient population.MethodsA total of 34 ACLF patients with COVID-19 admitted to these three hospitals from December 2022 to August 2023 were included as the ACLF+COVID-19 group. Additionally, 34 age-, gender-, etiology-, and Model for End-Stage Liver Disease-Sodium (MELD-Na) score-matched ACLF patients were screened from 286 ACLF patients as the ACLF group. From 382 COVID-19 patients, 34 were selected as the COVID-19 group, matching the ACLF+COVID-19 group in age, gender, and illness severity. Clinical features of these three groups were compared, with the primary measure being the 28-day mortality rate in the ACLF patients and the secondary measures including clinical symptoms, laboratory tests, comorbidities, and complications in three groups.ResultsCompared with the ACLF group, the ACLF+COVID-19 group had significantly higher incidence rates of fever, cough, sputum production, fatigue, and hypoxemia (all p<0.01). Patients in the ACLF+COVID-19 group were more likely to have hepatic encephalopathy (p=0.015), lower platelet count (p=0.016) and elevated IL-6 level (p=0.026), and higher MELD-Na score (p=0.041) one week after admission, but without a significant increase in 28-day mortality rate (p=0.16).ConclusionsACLF patients with COVID-19 have increased risk for thrombocytopenia, more obvious inflammatory response, and rapid disease progression 1 week after admission, but the 28-day mortality rate is similar to that of ACLF patients without COVID-19. |
| format | Article |
| id | doaj-art-0807ed0ce34c45ae9ecedf842ec7e474 |
| institution | DOAJ |
| issn | 2235-2988 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Cellular and Infection Microbiology |
| spelling | doaj-art-0807ed0ce34c45ae9ecedf842ec7e4742025-08-20T02:56:54ZengFrontiers Media S.A.Frontiers in Cellular and Infection Microbiology2235-29882025-01-011410.3389/fcimb.2024.14719741471974Clinical characteristics and the role of IL-6 in acute-on-chronic liver failure patients with or without COVID-19: a multicenter paired cohort studyRuoyu Yao0Guofen Xu1Xiujuan Fu2Wenrui Zhang3Han Wang4Yu Chen5Jia Yao6Department of Gastroenterology, Third Hospital of Shanxi Medical University, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Tongji Shanxi Hospital, Taiyuan, ChinaDepartment of Gastroenterology, Third Hospital of Shanxi Medical University, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Tongji Shanxi Hospital, Taiyuan, ChinaDepartment of Gastroenterology, Third Hospital of Shanxi Medical University, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Tongji Shanxi Hospital, Taiyuan, ChinaDepartment of Gastroenterology, Third Hospital of Shanxi Medical University, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Tongji Shanxi Hospital, Taiyuan, ChinaDepartment of Gastroenterology, Third Hospital of Shanxi Medical University, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Tongji Shanxi Hospital, Taiyuan, ChinaFourth Department of Liver Disease (Difficult and Complicated Liver Diseases and Artificial Liver Center), Beijing You’an Hospital Affiliated to Capital Medical University, Beijing, ChinaDepartment of Gastroenterology, Third Hospital of Shanxi Medical University, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Tongji Shanxi Hospital, Taiyuan, ChinaBackground and AimsThe impact of coronavirus disease 2019 (COVID-19) on patients with acute-on-chronic liver failure (ACLF) remains unclear. To investigate the clinical characteristics of patients with ACLF complicated with COVID-19 in order to provide evidence for the precise treatment of this patient population.MethodsA total of 34 ACLF patients with COVID-19 admitted to these three hospitals from December 2022 to August 2023 were included as the ACLF+COVID-19 group. Additionally, 34 age-, gender-, etiology-, and Model for End-Stage Liver Disease-Sodium (MELD-Na) score-matched ACLF patients were screened from 286 ACLF patients as the ACLF group. From 382 COVID-19 patients, 34 were selected as the COVID-19 group, matching the ACLF+COVID-19 group in age, gender, and illness severity. Clinical features of these three groups were compared, with the primary measure being the 28-day mortality rate in the ACLF patients and the secondary measures including clinical symptoms, laboratory tests, comorbidities, and complications in three groups.ResultsCompared with the ACLF group, the ACLF+COVID-19 group had significantly higher incidence rates of fever, cough, sputum production, fatigue, and hypoxemia (all p<0.01). Patients in the ACLF+COVID-19 group were more likely to have hepatic encephalopathy (p=0.015), lower platelet count (p=0.016) and elevated IL-6 level (p=0.026), and higher MELD-Na score (p=0.041) one week after admission, but without a significant increase in 28-day mortality rate (p=0.16).ConclusionsACLF patients with COVID-19 have increased risk for thrombocytopenia, more obvious inflammatory response, and rapid disease progression 1 week after admission, but the 28-day mortality rate is similar to that of ACLF patients without COVID-19.https://www.frontiersin.org/articles/10.3389/fcimb.2024.1471974/fullacute-on-chronic liver failureCOVID-19SARS-CoV-2mortalityprognosisIL-6 |
| spellingShingle | Ruoyu Yao Guofen Xu Xiujuan Fu Wenrui Zhang Han Wang Yu Chen Jia Yao Clinical characteristics and the role of IL-6 in acute-on-chronic liver failure patients with or without COVID-19: a multicenter paired cohort study Frontiers in Cellular and Infection Microbiology acute-on-chronic liver failure COVID-19 SARS-CoV-2 mortality prognosis IL-6 |
| title | Clinical characteristics and the role of IL-6 in acute-on-chronic liver failure patients with or without COVID-19: a multicenter paired cohort study |
| title_full | Clinical characteristics and the role of IL-6 in acute-on-chronic liver failure patients with or without COVID-19: a multicenter paired cohort study |
| title_fullStr | Clinical characteristics and the role of IL-6 in acute-on-chronic liver failure patients with or without COVID-19: a multicenter paired cohort study |
| title_full_unstemmed | Clinical characteristics and the role of IL-6 in acute-on-chronic liver failure patients with or without COVID-19: a multicenter paired cohort study |
| title_short | Clinical characteristics and the role of IL-6 in acute-on-chronic liver failure patients with or without COVID-19: a multicenter paired cohort study |
| title_sort | clinical characteristics and the role of il 6 in acute on chronic liver failure patients with or without covid 19 a multicenter paired cohort study |
| topic | acute-on-chronic liver failure COVID-19 SARS-CoV-2 mortality prognosis IL-6 |
| url | https://www.frontiersin.org/articles/10.3389/fcimb.2024.1471974/full |
| work_keys_str_mv | AT ruoyuyao clinicalcharacteristicsandtheroleofil6inacuteonchronicliverfailurepatientswithorwithoutcovid19amulticenterpairedcohortstudy AT guofenxu clinicalcharacteristicsandtheroleofil6inacuteonchronicliverfailurepatientswithorwithoutcovid19amulticenterpairedcohortstudy AT xiujuanfu clinicalcharacteristicsandtheroleofil6inacuteonchronicliverfailurepatientswithorwithoutcovid19amulticenterpairedcohortstudy AT wenruizhang clinicalcharacteristicsandtheroleofil6inacuteonchronicliverfailurepatientswithorwithoutcovid19amulticenterpairedcohortstudy AT hanwang clinicalcharacteristicsandtheroleofil6inacuteonchronicliverfailurepatientswithorwithoutcovid19amulticenterpairedcohortstudy AT yuchen clinicalcharacteristicsandtheroleofil6inacuteonchronicliverfailurepatientswithorwithoutcovid19amulticenterpairedcohortstudy AT jiayao clinicalcharacteristicsandtheroleofil6inacuteonchronicliverfailurepatientswithorwithoutcovid19amulticenterpairedcohortstudy |